REGULATORY

• Japan Approves J&J’s Lazcluze, Genmab’s Tivdak, and More
  March 28, 2025

• Japan Won’t Ban Red No. 3 for Now but Asks Industry for Self-Inspections
  March 27, 2025

• It’s Time to Review Conditional Approval System for Regenerative Medicines: MHLW Official
  March 27, 2025

• PMDA Stepping Up Efforts to Woo Overseas Startups to Japan
  March 27, 2025

• MHLW Presents Expected Roles of Clinical Research Hospitals towards Criteria Review
  March 26, 2025

• Raise Deduction Cap for Self-Medication Tax Break: OTC Industry Chief
  March 26, 2025

• NCC President Nakagama to Lead AMED from April
  March 26, 2025

• Pariet’s Nonprescription Versions Approved 6 Years after Discussions Start
  March 25, 2025

• AMED President Mishima Hints at Resignation
  March 25, 2025

• FPMAJ Prods Drastic Review of Fiscal Framework before Honebuto 2025
  March 25, 2025

• Difficult to “Visualize” Distribution, Production Costs in NHI Prices: Minister
  March 25, 2025

• MHLW Panel Discusses Ways to Promote Clinical Trials
  March 24, 2025

• PMDA Issues Guidance for Pediatric Drug Development
  March 24, 2025

• US Chamber Raises Japan’s Pharma Policy as Unfair Trade Practice, Prods Federal Govt for Action
  March 19, 2025

• MHLW to Investigate Pharmaceutical Ad Regulations in US, Europe
  March 18, 2025

• MHLW Council OKs Public Knowledge Filing for Anaemetro’s Pediatric Use
  March 17, 2025

• PMDA Reviewing Safety Risks of Paxlovid/Xtandi Concurrent Use
  March 17, 2025

• MHLW Panel OKs List of “High-Priority” Vaccines, including Norovirus Jabs
  March 14, 2025

• JPA Asks for Price Penalty for High-Cost Meds with Packaging Unaligned to Dosing
  March 14, 2025

• Chuikyo to Discuss Potential Pricing Steps to Deal with Higher Costs of Japan-Made APIs
  March 13, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 25
• 26
• 27
• 28
• 29
• 30
• 31
• 32
• 33
• …
• Next ›
• 最終 »